ImmunityBio(IBRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Full year net product revenue for ANKTIVA was $113 million, representing a 700% year-over-year increase from $14.1 million in 2024 [39][47] - Unit sales volume increased by 750% over the same period, indicating revenue growth driven by clinical adoption rather than pricing [39][47] - The company closed the year with a 20% quarter-over-quarter revenue growth from Q3 to Q4, demonstrating sustained commercial momentum [40][47] Business Line Data and Key Metrics Changes - ANKTIVA is the lead commercial asset and backbone of the company's platform, with strong uptake among urologists and oncologists treating BCG-unresponsive non-muscle invasive bladder cancer [41][42] - The favorable tolerability profile and durable response of ANKTIVA have led to repeat prescribing behavior among physicians, indicating confidence in the product [42] Market Data and Key Metrics Changes - ANKTIVA is now authorized across 33 countries, including major regulatory jurisdictions such as the United States, the United Kingdom, Saudi Arabia, and the European Union [40][44] - The European Commission granted conditional marketing authorization for ANKTIVA, opening access to a large patient population across 27 EU member states [43][44] Company Strategy and Development Direction - The company aims to grow from a commercial stage immunotherapy business into a diversified oncology platform, leveraging three platform technologies: ANKTIVA, CAR-NK cell therapy, and DNA vaccine vector technology [50][52] - The strategy includes pursuing label expansions for BCG-naïve bladder cancer and international expansion for non-small cell lung cancer [50][52] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significant progress made in converting revenue growth into a narrowing loss profile, with a net loss attributable to common stockholders reduced to $351.4 million from $413.6 million in 2024 [49] - The company is preparing to launch ANKTIVA in Saudi Arabia for both lung and bladder cancers, recognizing the ongoing global challenges but emphasizing the importance of continuing operations [46] Other Important Information - The company has established a partnership with Accord Healthcare to facilitate rapid commercial launch across Europe, leveraging their established infrastructure and relationships [44] - An expanded access program for recombinant BCG has been launched, with over 500 patients already treated [53] Q&A Session Summary Question: What is the commercial outlook for ANKTIVA in the U.S. market? - The U.S. remains the largest and most mature commercial market for ANKTIVA, with significant room for continued penetration as awareness grows among urology and oncology communities [43] Question: How is the company addressing the global shortage of BCG? - The company has launched an FDA-authorized expanded access program for recombinant BCG, with approximately 100 clinical sites active or activating [53] Question: What are the key milestones for the upcoming year? - The company plans to submit a BLA for the BCG-naïve indication in Q4 2026, which would significantly broaden the addressable market for bladder cancer [54]